Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.

STUDY OBJECTIVES To determine the risk factors and frequency of intracranial hemorrhage among patients undergoing thrombolysis for pulmonary embolism. DESIGN A retrospective descriptive and controlled analysis. SETTING Hospitalized patients at centers in the United States, Canada, and Italy. PATIENTS All had evidence of pulmonary embolism on perfusion scans or angiography. INTERVENTIONS None. MEASUREMENTS AND RESULTS Data were analyzed on 312 patients from five previously reported studies of pulmonary embolism thrombolysis. The frequency of intracranial hemorrhage up to 14 days after pulmonary embolism thrombolysis was 6 of 312 or 1.9% (95% confidence interval, 0.7 to 4.1%). Two of six intracranial hemorrhages were fatal. Two of the six patients received thrombolysis in violation of the protocol because they had pre-existing, known intracranial disease. Average diastolic BP at the time of hospital admission was significantly elevated in patients who developed an intracranial hemorrhage (90.3 +/- 15.1 mm Hg) compared with those who did not (77.6 +/- 10.9 mm Hg; p = 0.04). Other baseline characteristics and laboratory data were similar in both groups. Decreased level of consciousness, hemiparesis, and visual field deficits were the most common clinical signs of intracranial hemorrhage. CONCLUSIONS Intracranial hemorrhage after pulmonary embolism thrombolysis is an infrequent but often grave complication. Meticulous patient screening before administering thrombolysis is imperative. Diastolic hypertension at the time of hospital admission is a risk factor for intracranial hemorrhage after pulmonary embolism thrombolysis.

[1]  P. Mombaerts,et al.  Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. , 1988, Circulation.

[2]  S. Goldhaber,et al.  Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. , 1994, Chest.

[3]  B. Hyman,et al.  Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .

[4]  F. Schiele,et al.  Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. , 1993, Journal of the American College of Cardiology.

[5]  J. Garcìa,et al.  Pathology of hypertensive arteriopathy. , 1992, Neurosurgery clinics of North America.

[6]  E. Braunwald,et al.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.

[7]  Benraad Ah,et al.  POTASSIUM CHLORIDE AND INTESTINAL ULCERATION. , 1965 .

[8]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[9]  J. Toole,et al.  Clinical and computerized tomographic study of hypertensive intracerebral hemorrhage. , 1978, Archives of neurology.

[10]  C M O'Connor,et al.  CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. , 1991, Radiology.

[11]  G. Meyer,et al.  Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. , 1992, The American journal of cardiology.

[12]  J. Gore,et al.  Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction , 1995, Neurology.

[13]  R. Califf,et al.  Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. , 1989, Chest.

[14]  J. Hirsh,et al.  A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. , 1990, Chest.

[15]  S. Goldhaber,et al.  Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. , 1992, Journal of the American College of Cardiology.

[16]  R. Tracy,et al.  Intracerebral hemorrhage related to cerebral amyloid angiopathy and T‐PA treatment , 1991, Annals of neurology.

[17]  J. Loscalzo,et al.  Perspectives on Treatment of Acute Pulmonary Embolism with Tissue Plasminogen Activator , 1987, Seminars in thrombosis and hemostasis.

[18]  Daniel B Hier,et al.  Anticoagulant‐related intracerebral hemorrhage , 1985, Neurology.

[19]  E. Braunwald,et al.  RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM , 1988, The Lancet.

[20]  G. Simonneau,et al.  Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. , 1994, Chest.

[21]  E. Lesaffre,et al.  Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. , 1992, Journal of the American College of Cardiology.

[22]  J. Loscalzo,et al.  Thrombolytic therapy of acute pulmonary embolism: current status and future potential. , 1987, Journal of the American College of Cardiology.

[23]  E. Freis Hypertension. A challenge in preventive cardiology. , 1973, Circulation.

[24]  E. Braunwald,et al.  ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR , 1986, The Lancet.